Even with this limitation, we concluded that ANA-SA5 is an attractive candidate for clinical use in AD treatment and prevention, as well as ANA-TA9 and JAL-TA9, previously identified as Catalytides. The gene discussed is BTG3; the disease is Alzheimer disease.